These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32590314)

  • 1. Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey.
    Ricardo A; Carnero Contentti E; Anabel SB; Adrian LP; Orlando G; Fernando H; Víctor R; Fernando G; Ignacio RJ
    Mult Scler Relat Disord; 2020 Sep; 44():102310. PubMed ID: 32590314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience of South American MS and/or NMOSD experts in practice during the COVID-19 pandemic: Focus on Telemedicine.
    Alonso R; Carvajal R; Boaventura M; Galleguillos L
    Mult Scler Relat Disord; 2021 Feb; 48():102702. PubMed ID: 33360914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources.
    Viswanathan S
    Mult Scler Relat Disord; 2020 Sep; 44():102353. PubMed ID: 32653804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis and neuromyelitis optica spectrum disorder testing and treatment availability in Latin America.
    Rojas JI; Gracia F; Patrucco L; Alonso R; Carnero Contentti E; Cristiano E
    Neurol Res; 2021 Dec; 43(12):1081-1086. PubMed ID: 34240685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic.
    Abboud H; Zheng C; Kar I; Chen CK; Sau C; Serra A
    Mult Scler Relat Disord; 2020 Sep; 44():102249. PubMed ID: 32526698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice.
    Carnero Contentti E; Rojas JI; Cristiano E; Marques VD; Flores-Rivera J; Lana-Peixoto M; Navas C; Papais-Alvarenga R; Sato DK; Soto de Castillo I; Correale J
    Mult Scler Relat Disord; 2020 Oct; 45():102428. PubMed ID: 32763842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
    ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
    Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.
    Alonso R; Silva B; Garcea O; Diaz PEC; Dos Passos GR; Navarro DAR; Valle LAG; Salinas LCR; Negrotto L; Luetic G; Tkachuk VA; Míguez J; de Bedoya FHD; Goiry LG; Sánchez NER; Burgos M; Steinberg J; Balbuena ME; Alvarez PM; López PA; Ysrraelit MC; León RA; Cohen AB; Gracia F; Molina O; Casas M; Deri NH; Pappolla A; Patrucco L; Cristiano E; Tavolini D; Nadur D; Granda AMT; Weiser R; Cassará FP; Sinay V; Rodríguez CC; Lazaro LG; Menichini ML; Piedrabuena R; Escobar GO; Carrá A; Chertcoff A; Pujols BS; Vrech C; Tarulla A; Carvajal R; Mainella C; Becker J; Peeters LM; Walton C; Serena MA; Nuñez S; Rojas JI
    Mult Scler Relat Disord; 2021 Jun; 51():102886. PubMed ID: 33744758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
    Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
    Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of venous thromboembolism in neuromyelitis optica patients hospitalized for acute relapse.
    Farber RS; Gross R; Zakin E; Fabian M
    Mult Scler; 2017 Jun; 23(7):988-994. PubMed ID: 27672136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders.
    Fan M; Qiu W; Bu B; Xu Y; Yang H; Huang D; Lau AY; Guo J; Zhang MN; Zhang X; Yang CS; Chen J; Zheng P; Liu Q; Zhang C; Shi FD
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 in MS and NMOSD: A multicentric online national survey in Chile.
    Ciampi E; Uribe-San-Martín R; Soler B; Fernández R; García P; Navarrete-Asenjo C; Tirapegui JM; Torres R; Polanco J; Suárez F; Cuello MJ; Cárcamo C
    Mult Scler Relat Disord; 2020 Oct; 45():102392. PubMed ID: 32683306
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment of mental health, knowledge, and attitude of patients with multiple sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus.
    Shaygannejad V; Afshari-Safavi A; Hatef B
    Neurol Sci; 2021 Jul; 42(7):2891-2901. PubMed ID: 33219424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.
    Tomczak A; Han MH
    Mult Scler Relat Disord; 2020 Oct; 45():102347. PubMed ID: 32645636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society.
    Vukusic S; Marignier R; Ciron J; Bourre B; Cohen M; Deschamps R; Guillaume M; Kremer L; Pique J; Carra-Dalliere C; Michel L; Leray E; Guennoc AM; Laplaud D; Androdias G; Bensa C; Bigaut K; Biotti D; Branger P; Casez O; Daval E; Donze C; Dubessy AL; Dulau C; Durand-Dubief F; Hebant B; Kwiatkowski A; Lannoy J; Maarouf A; Manchon E; Mathey G; Moisset X; Montcuquet A; Roux T; Maillart E; Lebrun-Frenay C
    Mult Scler; 2023 Jan; 29(1):37-51. PubMed ID: 36345839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Optic Neuritis with Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Korea.
    Kim H; Park KA; Oh SY; Min JH; Kim BJ
    Korean J Ophthalmol; 2019 Feb; 33(1):82-90. PubMed ID: 30746915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: A systematic review.
    Mirmosayyeb O; Ghaffary EM; Vaheb S; Pourkazemi R; Shaygannejad V
    Rev Neurol (Paris); 2023 Apr; 179(4):265-281. PubMed ID: 36658048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OMG: MS, NMOSD, and MOG.
    Lewis SL
    Continuum (Minneap Minn); 2019 Jun; 25(3):594-595. PubMed ID: 31162306
    [No Abstract]   [Full Text] [Related]  

  • 19. Peripheral CD19
    Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
    J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromyelitis optica spectrum disorder (NMOSD): A new concept.
    de Sèze J; Kremer L; Collongues N
    Rev Neurol (Paris); 2016; 172(4-5):256-62. PubMed ID: 27157418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.